CMV

COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study
18/09/2025
Ozempic ® (once-weekly injectable semaglutide) was associated with a 23% reduced risk of heart attack, stroke and death in people with type 2 diabetes and cardiovascular disease on Medicare versus dulaglutide 1 Data [...]
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland
18/09/2025
STAFFORD, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Climat : la Science Based Targets initiative (SBTi) valide les objectifs à court terme d’EUROAPI
18/09/2025
Communiqué de presse Réduction de 42% des émissions de gaz à effet de serre des Scopes 1 et 2 d’ici à 2030 (par rapport à 2022) Réduction de 25% des émissions de gaz à effet de serre du Scope 3 d’ici à 2030 (par rapport [...]
Science Based Targets initiative (SBTi) validates EUROAPI’s near-term climate targets
18/09/2025
Press Release 42% reduction in Scope 1 and 2 Greenhouse Gas emissions by 2030 (vs. 2022) 25% reduction in Scope 3 GHG emissions by 2030 (vs. 2022) September 18, 2025 - EUROAPI’s near-term science-based emission [...]
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
18/09/2025
89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe Metabolic Dysfunction-Associated Steatohepatitis (MASH), one of the most prevalent comorbidities of obesity Acquisition [...]
89bio, Inc. Announces Agreement to be Acquired by Roche
18/09/2025
– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash [...]
Concurrent Publications in Nature and Nature Medicine Highlight Advances in Blood Pressure Regulation after Spinal Cord Injury Using ONWARD ARC-IM Therapy
18/09/2025
Detailed results from clinical feasibility studies show immediate improvement in blood pressure stability and durable reduction of hypotensive symptoms, resulting in improved quality of life Most people living with [...]
Imprivata, éditeur international de solutions de gestion des accès, se développe sur le marché français pour répondre à la demande croissante en matière de sécurité et de conformité
18/09/2025
Initialement axées sur les soins de santé, les solutions Imprivata permettent un accès clinique rapide et sécurisé aux services informatiques afin de soutenir le programme CaRE et en particulier le domaine HospiConnect [...]
Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management
18/09/2025
SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, received the “Excellence Award” at Gilead Sciences, Inc.’s (“ [...]
EssilorLuxottica: Le partenariat EssilorLuxottica et Meta se poursuit avec de nouvelles lunettes avec IA qui préfigurent le futur
18/09/2025
Le partenariat EssilorLuxottica et Meta se poursuit avec de nouvelles lunettes avec IA qui préfigurent le futur Les deux groupes élargissent leur gamme de « wearables » avec de nouveaux produits dévoilés lors de Meta [...]
EssilorLuxottica: EssilorLuxottica and Meta build on their successful partnership with new AI glasses that offer a glimpse into the future
18/09/2025
EssilorLuxottica and Meta build on their successful partnership with new AI glasses that offer a glimpse into the future The two companies continue to grow their wearables lineup with new products revealed at Meta [...]
Fangzhou Named ‘Outstanding Growth Story in Hong Kong Stocks’ at China Capital Market Development Forum 2025
18/09/2025
SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, was recognized as an “Outstanding Growth Story in Hong Kong [...]
Aurora Spine Announces Launch of its DEXA-L™ Anterior Lumbar Interbody Fusion Device
18/09/2025
Please click here to view image CARLSBAD, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional [...]
Are Women on the Frontline of Antimicrobial Resistance?
17/09/2025
LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- National Patient Survey of Women’s Urinary Tract Infection (UTI) and Prenatal Screening reveals women suffering from UTI concerned about immediate antibiotic prescribing and [...]
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
17/09/2025
REDWOOD CITY, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today [...]
Vaxart Appoints W. Mark Watson as Lead Independent Director
17/09/2025
In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board’s interests with stockholders Vaxart encourages all stockholders of record on July 29, 2025, who have not yet voted [...]
Regional Health Properties, Inc. Completes Repurchases of 12.5% Series B Cumulative Redeemable Preferred Shares
17/09/2025
Atlanta, GA, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCQB: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB) (OTCQB: RHEPZ) today announced it has completed the repurchase of 366,359 shares [...]
NANOBIOTIX annonce de nouveaux résultats de Phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle en traitement de deuxième ligne ou plus chez des patients atteints de mélanome cutané résistant aux anti-PD-1
17/09/2025
Les données ont montré un profil de sécurité favorable et des signaux préliminaires d’efficacité dans une population lourdement prétraitée dont le cancer était en progression malgré plusieurs lignes de traitement, [...]
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
17/09/2025
Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1 Recommended phase 2 dose (RP2D) [...]

Pages